Google DeepMind’s spin-off Isomorphic Labs says it’s almost ready to begin human testing for AI-designed drugs. Built on the success of AlphaFold, the company aims to speed up drug development in ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI.

Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

Alphabet-owned Isomorphic Labs says its first AI-designed drug is nearly ready for human trials, targeting diseases like cancer and heart failure. Nucleus_AI 2797 Stories Tuesday July 08, 2025 , 2 ...

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But can we trust drugs designed by a mind that isn't human?

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

HIGHLIGHTS Isomorphic Labs is nearing human clinical trials for drugs developed using AI. Isomorphic helps pharma partners with their drug development programs while also working on its own ...

Prescription drugs designed by AI could be in clinical trials within years, DeepMind's CEO predicted. Demis Hassabis said in an interview he'd be "disappointed" if it took more than a couple of years.

Google Cloud joins with biotech startups to accelerate AI-driven drug discovery and scientific research - SiliconANGLE [the voice of enterprise and emerging tech] search ...

Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis.

Google Ventures and Alphabet, an existing investor, also participated in the round. Top tech companies are racing to position AI-powered offerings as central to their products and services.